Liquidia (NASDAQ:LQDA) General Counsel Russell Schundler Sells 13,692 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) General Counsel Russell Schundler sold 13,692 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $389,948.16. Following the transaction, the general counsel directly owned 602,841 shares of the company’s stock, valued at approximately $17,168,911.68. This trade represents a 2.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Down 3.1%

NASDAQ:LQDA traded down $0.86 during trading hours on Tuesday, reaching $26.81. 3,092,611 shares of the company traded hands, compared to its average volume of 5,078,983. The business’s 50-day moving average price is $63.40 and its two-hundred day moving average price is $61.76. The stock has a market capitalization of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61. Liquidia Corporation has a 1 year low of $21.94 and a 1 year high of $93.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Get Liquidia alerts:

Liquidia (NASDAQ:LQDA – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same period last year, the firm posted ($0.49) earnings per share. The company’s revenue was up 1842.1% compared to the same quarter last year. Analysts predict that Liquidia Corporation will post 2.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on LQDA. Stephens set a $130.00 price target on Liquidia in a research report on Friday, July 24th. Bank of America upped their price target on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. HC Wainwright cut their price objective on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, October 2nd. BTIG Research lowered shares of Liquidia from a “buy” rating to a “neutral” rating in a research note on Thursday, October 1st. Finally, Jefferies Financial Group upgraded shares of Liquidia to a “strong-buy” rating in a research note on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $83.69.

Check Out Our Latest Stock Analysis on Liquidia

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Liquidia during the 2nd quarter valued at $29,694,000. Eversept Partners LP boosted its stake in Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after purchasing an additional 167,949 shares during the last quarter. Seven Fleet Capital Management LP increased its holdings in shares of Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after purchasing an additional 51,727 shares in the last quarter. Finally, Pale Fire Capital SE increased its holdings in shares of Liquidia by 2.4% in the 1st quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock worth $14,657,000 after purchasing an additional 8,985 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).

Featured Articles

• Five stocks we like better than Liquidia
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.